{"gene":"EBF3","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2006,"finding":"EBF3 directly binds the p21(cip1/waf1) promoter and regulates transcription from both p21(cip1/waf1) and p27(kip1) promoters, inducing cell cycle arrest and apoptosis with caspase-3 activation; cyclin-dependent kinase inhibitors p27(kip1) and p57(kip2) are persistently activated while cell survival/proliferation genes are suppressed.","method":"Reporter assays, chromatin immunoprecipitation (ChIP), overexpression with functional readouts (cell cycle analysis, caspase-3 activation)","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — direct promoter binding by ChIP + reporter assay + functional phenotype with defined targets","pmids":["17018599"],"is_preprint":false},{"year":2016,"finding":"De novo missense variants in EBF3 affecting a conserved zinc finger motif reduce transcriptional activity and the ability to form heterodimers with wild-type EBF3, establishing that DNA binding and dimerization are required for EBF3 function in brain development.","method":"Transactivation (luciferase) assays, heterodimer formation assays with mutant proteins in cell lines, structural modeling","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal functional assays (transcriptional activation, dimerization) across two independent publications","pmids":["28017370","28017372","28017373"],"is_preprint":false},{"year":2016,"finding":"EBF3 missense mutations affecting the DNA-binding domain cause mislocalization of mutant proteins to the cytoplasm and reduce chromatin association, as demonstrated by subcellular fractionation; mutant EBF3 has reduced genome-wide DNA binding and gene-regulatory activity by ChIP-seq and RNA-seq.","method":"Subcellular fractionation, in situ chromatin association assay, ChIP-seq, RNA-seq, transactivation assays in HEK293T cells","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (fractionation, ChIP-seq, RNA-seq, reporter assay) in a single rigorous study","pmids":["28017373"],"is_preprint":false},{"year":2014,"finding":"Ebf3 is a target of miR-218 during dopaminergic (DA) neuron development; overexpression of Ebf3 at the neural precursor stage increases TH+ DA neuron number, while suppression reduces it, and miR-218-mediated regulation of Ebf3 controls terminal differentiation of DA neurons.","method":"Overexpression and knockdown in ES cell differentiation system, miRNA target validation, cell counting of TH+ neurons","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2–3 — gain/loss-of-function with specific cellular phenotype, miRNA-target relationship shown","pmids":["25192643"],"is_preprint":false},{"year":2017,"finding":"Ebf3 is a target gene of the transcription factor Prdm8; Ebf3 knockdown causes severe defects in leading process formation and inhibits the multipolar-to-bipolar transition of migrating neocortical neurons. Ebf3 positively regulates NeuroD1 transcription and NeuroD1 overexpression partially rescues the migration defect.","method":"In utero electroporation-based knockdown, morphological analysis of migrating neurons, NeuroD1 overexpression rescue","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular phenotype (migration defect) and partial genetic rescue","pmids":["29113800"],"is_preprint":false},{"year":2018,"finding":"Ebf3 is expressed in CXCL12-abundant reticular (CAR)/LepR+ mesenchymal stem cells of bone marrow; deletion of Ebf3 in these cells impairs HSC niche function and causes osteosclerosis. Combined deletion of Ebf1 and Ebf3 leads to osteoblast differentiation of CAR cells with reduced HSC niche factor expression and complete marrow cavity occlusion, demonstrating that Ebf3 maintains mesenchymal stem cell identity and inhibits osteoblast differentiation.","method":"Conditional knockout mice, lineage tracing, histology, HSC functional assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with defined cellular and organismal phenotype, lineage tracing, replicated with double KO","pmids":["29563184"],"is_preprint":false},{"year":2018,"finding":"EBF3-EGFP fusion protein localizes predominantly to the nucleus when expressed in HepG2 cells, establishing nuclear localization of EBF3.","method":"Fluorescence microscopy and Western blot of nuclear/cytoplasmic fractions of transfected cells","journal":"Xi bao yu fen zi mian yi xue za zhi","confidence":"Low","confidence_rationale":"Tier 3 — single localization experiment, no functional consequence tested","pmids":["18845077"],"is_preprint":false},{"year":2021,"finding":"EBF3 directly binds the Vimentin promoter to transcriptionally upregulate it, promoting metastasis in nasopharyngeal carcinoma; EBF3 is epigenetically silenced by the EGR1/EZH2/HDAC9 complex via H3K27me3 at its promoter.","method":"ChIP, promoter reporter assays, RNA-seq, epigenetic complex characterization","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct promoter binding shown by ChIP, epigenetic regulation mechanism identified with complex components","pmids":["34906623"],"is_preprint":false},{"year":2023,"finding":"Bmal1 recruits EZH2 to the EBF3 promoter to enhance H3K27me3-mediated methylation and suppress EBF3 expression; EBF3 in turn binds the ALOX15 promoter to enhance its expression and promote ferroptosis, establishing the Bmal1/EZH2 → EBF3 → ALOX15 → ferroptosis axis in AML.","method":"ChIP, promoter reporter assays, knockdown/overexpression, in vivo xenograft model, ferroptosis biochemical assays","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-validated direct promoter binding at both steps of the pathway, in vivo confirmation","pmids":["37271497"],"is_preprint":false},{"year":2023,"finding":"CXCL12 deletion from Ebf3+/LepR+ CAR cells markedly reduces HSCs and impairs their ability to generate B cell progenitors; CXCL12 maintains lymphoid-biased HSC repopulating ability in vitro, demonstrating that CAR cell-derived CXCL12 is required for HSC localization and lymphoid-biased maintenance.","method":"Conditional CXCL12 deletion from Ebf3+ cells, transplantation assays, in vitro CXCL12 treatment of HSCs","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with specific cellular phenotype, transplantation rescue, in vitro validation","pmids":["37880234"],"is_preprint":false},{"year":2020,"finding":"Ebf3 is required in lateral plate mesenchyme cells (particularly tendon/connective tissue cells) at embryonic day 9.5–10.5 for sternum ossification; Ebf3 knockout leads to defective Runx2+ pre-osteoblast generation without affecting chondrogenesis, with upregulation of Egr1/2, Osr1 and Islet1+ cells and downregulation of Shox2.","method":"Knockout and conditional/temporal knockout mice, cell lineage analysis, gene expression profiling","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — conditional and temporal KO with defined cellular phenotype and downstream gene expression changes","pmids":["32398354"],"is_preprint":false},{"year":2024,"finding":"EBF3 binds the CNTNAP4 promoter and directly activates CNTNAP4 transcription, protecting dopaminergic neurons from apoptosis in a Parkinson's disease model; m6A methylation (regulated by FTO) controls EBF3 mRNA stability and expression.","method":"Luciferase reporter assay, ChIP, DNA pulldown assay, CNTNAP4 knockdown rescue experiment, in vivo MPTP mouse model","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct promoter binding confirmed by ChIP and DNA pulldown, functional rescue by target knockdown","pmids":["38479556"],"is_preprint":false},{"year":2025,"finding":"EBF3 transcriptionally activates ACADL by binding to its promoter, blocking nuclear YAP localization and canonical Hippo/YAP target genes (CTGF, CYR61, ANKRD1) to suppress breast cancer cell growth.","method":"Promoter binding assays, luciferase reporter, ACADL knockdown rescue, xenograft tumor model","journal":"Pathology, research and practice","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding shown, pathway placement via rescue experiment and in vivo model","pmids":["41270467"],"is_preprint":false},{"year":2025,"finding":"EBF3 transcriptionally represses CCL24 to remodel the tumor immune microenvironment in lung adenocarcinoma, reducing M2-like macrophage infiltration and increasing CD4+/CD8+ T cell recruitment; EBF3 also suppresses AKT and P38 phosphorylation.","method":"Overexpression/knockdown, ChIP/reporter assays for CCL24, conditioned medium macrophage polarization assay, syngeneic mouse model with immune flow cytometry, CCL24 rescue experiment","journal":"Cellular oncology","confidence":"Medium","confidence_rationale":"Tier 2 — direct transcriptional repression of CCL24 validated, in vivo rescue with exogenous CCL24 confirms mechanism","pmids":["42018103"],"is_preprint":false},{"year":2025,"finding":"SNORA47 interacts with EBF3 to facilitate translocation of ribosomal protein L11 (RPL11), which modulates c-Myc levels, establishing a SNORA47-EBF3-RPL11-c-Myc axis controlling breast cancer stemness.","method":"Co-immunoprecipitation/interaction assays, overexpression/knockdown with phenotypic readouts","journal":"Molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 — single lab, interaction assay without rigorous mechanistic follow-up of EBF3's direct role","pmids":["40264043"],"is_preprint":false},{"year":2022,"finding":"EBF3 missense variants disrupting the zinc finger domain (ZNF) fail to restore viability in Drosophila and impair transcriptional activation in luciferase assays, whereas the recurrent DBD variant p.Arg209Trp partially rescues fly viability and preserves transcriptional activation, establishing a genotype-severity correlation.","method":"In vivo Drosophila UAS-GAL4 rescue assays, in vitro luciferase transcriptional activation assays","journal":"Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 1–2 — two orthogonal functional assays (in vivo fly model + in vitro reporter) applied to multiple variants","pmids":["35340043"],"is_preprint":false},{"year":2017,"finding":"Missense variants in the zinc knuckle of EBF3's DNA binding domain reduce DNA affinity, as predicted by homology-based atomic modeling and molecular dynamics simulations, consistent with experimental data for the paralogous residue in EBF1.","method":"Homology-based structural modeling, molecular dynamics simulations","journal":"Cold Spring Harbor molecular case studies","confidence":"Low","confidence_rationale":"Tier 4 — computational/in silico prediction, no direct experimental validation of EBF3 structure","pmids":["28487885"],"is_preprint":false},{"year":2021,"finding":"EBF3 binds promoters of neurodevelopmental disorder (NDD) genes in neuronal cells as shown by ChIP-seq, with enrichment for binding NDD genes involved in gene regulation (p=7.43×10-6, OR=1.87).","method":"ChIP-seq in neuronal cells, gene enrichment analysis","journal":"Human genomics","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide ChIP-seq with statistical enrichment analysis in relevant cell type","pmids":["34256850"],"is_preprint":false},{"year":2024,"finding":"In zebrafish ebf3a loss-of-function mutants, the cerebellum, hypothalamus, and hindbrain are smaller, cerebellar activity is strongly increased, and genes marking olfactory sensory neurons, the lateral line, and cerebellar Purkinje neurons are significantly downregulated, establishing Ebf3's role in sensory system and cerebellar development.","method":"Loss-of-function zebrafish mutant, RNA-sequencing, brain activity imaging, behavioral assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined cellular and transcriptomic phenotype in an ortholog model","pmids":[],"is_preprint":true}],"current_model":"EBF3 is a nuclear transcription factor with an atypical zinc finger/helix-loop-helix DNA-binding domain that directly binds promoters of target genes (including p21, p27, CDKN1A, Vimentin, ALOX15, CNTNAP4, ACADL, CCL24) to activate or repress transcription; disease-causing mutations in its zinc finger or DNA-binding domain cause nuclear mislocalization, reduced chromatin association, and loss of transcriptional activation, leading to a neurodevelopmental syndrome (HADDS); in the bone marrow niche it maintains mesenchymal stem cell identity and prevents osteoblast differentiation; in neurons it regulates dopaminergic differentiation, neocortical neuronal migration via NeuroD1, and cerebellar/sensory development; and its expression is itself controlled by epigenetic mechanisms including EZH2/H3K27me3, m6A mRNA modification, and miRNA targeting."},"narrative":{"teleology":[{"year":2006,"claim":"Establishing that EBF3 is a direct transcriptional activator of cell cycle inhibitor genes answered the fundamental question of how EBF3 exerts growth-suppressive effects — by binding the p21 promoter and inducing p21/p27-dependent cell cycle arrest and apoptosis.","evidence":"ChIP showing direct p21 promoter binding, reporter assays, and cell cycle/caspase-3 analysis upon EBF3 overexpression","pmids":["17018599"],"confidence":"High","gaps":["Endogenous contexts where EBF3 regulates p21/p27 not defined","Whether EBF3-mediated apoptosis requires p21/p27 or operates through parallel targets not tested"]},{"year":2014,"claim":"Discovery that miR-218 targets Ebf3 during dopaminergic neuron differentiation established a post-transcriptional control layer and revealed EBF3 as a dose-sensitive regulator of terminal DA neuron fate.","evidence":"Gain- and loss-of-function in ES cell–derived DA neuron differentiation, miR-218 target validation, TH+ neuron quantification","pmids":["25192643"],"confidence":"Medium","gaps":["Direct Ebf3 transcriptional targets in DA neurons not identified","In vivo relevance of miR-218/Ebf3 axis in DA neuron development not tested"]},{"year":2016,"claim":"Identification of de novo EBF3 mutations in patients with neurodevelopmental disease, combined with demonstration that zinc finger and DNA-binding domain mutations abolish transcriptional activation, dimerization, nuclear retention, and genome-wide chromatin occupancy, established the molecular basis of HADDS and defined EBF3 as a haploinsufficient transcription factor requiring DNA binding and dimerization for function.","evidence":"Patient genetics, luciferase transactivation, dimerization assays, subcellular fractionation, ChIP-seq, and RNA-seq in HEK293T cells","pmids":["28017370","28017372","28017373"],"confidence":"High","gaps":["No crystal structure of the EBF3 DNA-binding domain to explain variant-specific effects","Neuronal cell-type–specific consequences of mutations not characterized"]},{"year":2017,"claim":"Showing that Ebf3 knockdown disrupts the multipolar-to-bipolar transition in migrating neocortical neurons and that NeuroD1 overexpression partially rescues this defect identified a specific downstream pathway through which EBF3 controls cortical neuron migration.","evidence":"In utero electroporation knockdown in mouse neocortex, morphological analysis, NeuroD1 rescue","pmids":["29113800"],"confidence":"Medium","gaps":["Whether EBF3 directly binds NeuroD1 promoter not shown","Cell-autonomous vs. non-autonomous effects not distinguished"]},{"year":2018,"claim":"Conditional deletion of Ebf3 (alone and with Ebf1) in CAR/LepR+ bone marrow mesenchymal cells revealed that EBF3 maintains mesenchymal stem cell identity and prevents osteoblast differentiation, directly linking EBF3 to hematopoietic niche function.","evidence":"Conditional knockout mice with lineage tracing, histology showing osteosclerosis, HSC functional assays","pmids":["29563184"],"confidence":"High","gaps":["Direct transcriptional targets mediating the anti-osteoblast program not identified","Relative contribution of EBF3 vs. EBF1 in single cells not resolved"]},{"year":2021,"claim":"ChIP-seq in neuronal cells revealed genome-wide enrichment of EBF3 binding at promoters of neurodevelopmental disorder genes, providing a mechanistic link between EBF3 transcriptional targets and the neurodevelopmental phenotype of HADDS patients.","evidence":"ChIP-seq in neuronal cells with statistical enrichment for NDD gene promoters","pmids":["34256850"],"confidence":"Medium","gaps":["Functional validation of individual NDD gene targets not performed","Whether EBF3 activates or represses these NDD targets not determined"]},{"year":2021,"claim":"Demonstration that the EGR1/EZH2/HDAC9 complex silences EBF3 via H3K27me3 at its promoter, and that EBF3 directly activates Vimentin transcription, established an epigenetic switch controlling EBF3 expression and identified a pro-metastatic transcriptional target.","evidence":"ChIP and reporter assays at the EBF3 and Vimentin promoters, epigenetic complex characterization in nasopharyngeal carcinoma","pmids":["34906623"],"confidence":"Medium","gaps":["Whether EZH2-mediated EBF3 silencing operates in normal developmental contexts not tested","Vimentin as sole mediator of metastatic phenotype not established"]},{"year":2022,"claim":"Functional testing of multiple EBF3 patient variants using Drosophila rescue and luciferase assays established a genotype-severity correlation, showing zinc finger mutations are more damaging than certain DNA-binding domain mutations.","evidence":"UAS-GAL4 rescue of Drosophila lethality with variant EBF3 constructs and luciferase transcriptional assays","pmids":["35340043"],"confidence":"Medium","gaps":["Drosophila model does not recapitulate human brain-specific phenotypes","Structural basis for differential severity of ZNF vs. DBD variants remains computational"]},{"year":2023,"claim":"The Bmal1/EZH2→EBF3→ALOX15 axis in AML cells extended the epigenetic regulation paradigm and identified EBF3 as a transcriptional activator of ALOX15 that promotes ferroptosis, providing a functional context beyond development.","evidence":"ChIP at EBF3 and ALOX15 promoters, knockdown/overexpression, ferroptosis assays, xenograft model in AML","pmids":["37271497"],"confidence":"Medium","gaps":["Whether EBF3-driven ferroptosis operates in non-malignant hematopoietic cells unknown","Specificity of Bmal1 recruitment of EZH2 to EBF3 vs. other loci not addressed"]},{"year":2023,"claim":"Conditional CXCL12 deletion from Ebf3+ cells demonstrated that the EBF3-marked CAR niche specifically maintains HSC localization and lymphoid-biased repopulating ability via CXCL12, refining the niche model.","evidence":"Conditional CXCL12 KO from Ebf3-Cre+ cells, transplantation assays, in vitro CXCL12 treatment","pmids":["37880234"],"confidence":"High","gaps":["Whether EBF3 directly regulates CXCL12 transcription not tested","Heterogeneity within Ebf3+ CAR cells not resolved"]},{"year":2024,"claim":"Discovery that FTO-regulated m6A modification controls EBF3 mRNA stability, and that EBF3 directly activates CNTNAP4 to protect DA neurons from apoptosis, added a post-transcriptional regulatory layer and a neuroprotective target gene.","evidence":"ChIP and DNA pulldown at the CNTNAP4 promoter, CNTNAP4 knockdown rescue, MPTP Parkinson's disease mouse model","pmids":["38479556"],"confidence":"Medium","gaps":["Specific m6A sites on EBF3 mRNA not mapped","Whether CNTNAP4 activation is relevant to HADDS neuropathology unknown"]},{"year":2025,"claim":"Identification of EBF3 as a transcriptional activator of ACADL (blocking YAP nuclear localization) and a repressor of CCL24 (remodeling tumor immune microenvironment) expanded the target repertoire to include Hippo pathway modulation and immune regulation.","evidence":"Promoter binding/reporter assays, rescue experiments, xenograft and syngeneic mouse models in breast and lung cancer","pmids":["41270467","42018103"],"confidence":"Medium","gaps":["Whether ACADL-mediated YAP suppression is relevant to non-cancer contexts not addressed","Direct mechanism by which EBF3 represses (vs. activates) transcription at CCL24 not elucidated"]},{"year":null,"claim":"Key unresolved questions include the structural basis of EBF3 DNA recognition and dimerization, the complete neuronal target gene program explaining HADDS pathogenesis, the mechanism by which EBF3 switches between transcriptional activation and repression, and whether EBF3's roles in mesenchymal stem cell maintenance and neuronal development share common transcriptional targets.","evidence":"","pmids":[],"confidence":"High","gaps":["No experimentally determined structure of EBF3","Genome-wide target analysis in disease-relevant neuronal subtypes lacking","Activation vs. repression mechanism at different promoters unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,7,8,11,12,13,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,7,8,11,12,13]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,6]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[2,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,2,7,8,11,12,13,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,4,5,10,18]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,8]}],"complexes":[],"partners":["EBF1","EZH2","NEUROD1","PRDM8"],"other_free_text":[]},"mechanistic_narrative":"EBF3 is a sequence-specific transcription factor that controls cell fate decisions in neuronal, mesenchymal, and hematopoietic lineages by directly binding target gene promoters to activate or repress transcription. It recognizes DNA through an atypical zinc finger/helix-loop-helix domain and functions as a homodimer or heterodimer; disease-causing mutations in the zinc finger or DNA-binding domain cause cytoplasmic mislocalization, reduced chromatin association, and impaired transcriptional activation, resulting in the neurodevelopmental disorder HADDS (hypotonia, ataxia, and delayed development syndrome) [PMID:28017370, PMID:28017373, PMID:35340043]. In bone marrow, EBF3 maintains CXCL12-abundant reticular mesenchymal stem cell identity and suppresses osteoblast differentiation, while in neurons it promotes dopaminergic differentiation, regulates neocortical migration through NeuroD1 activation, and controls cerebellar and sensory neuron development [PMID:29563184, PMID:25192643, PMID:29113800]. EBF3 directly activates diverse target promoters including CDKN1A/p21, Vimentin, ALOX15, CNTNAP4, and ACADL, and represses CCL24; its own expression is regulated epigenetically by EZH2-mediated H3K27 trimethylation and post-transcriptionally by m6A modification and miR-218 [PMID:17018599, PMID:34906623, PMID:37271497, PMID:38479556, PMID:42018103]."},"prefetch_data":{"uniprot":{"accession":"Q9H4W6","full_name":"Transcription factor COE3","aliases":["Early B-cell factor 3","EBF-3","Olf-1/EBF-like 2","O/E-2","OE-2"],"length_aa":596,"mass_kda":64.9,"function":"Transcriptional activator (PubMed:28017370, PubMed:28017372, PubMed:28017373). Recognizes variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3' (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H4W6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EBF3","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EBF3","total_profiled":1310},"omim":[{"mim_id":"620491","title":"MATURIN, NEURAL PROGENITOR DIFFERENTIATION REGULATOR HOMOLOG; MTURN","url":"https://www.omim.org/entry/620491"},{"mim_id":"617330","title":"HYPOTONIA, ATAXIA, AND DELAYED DEVELOPMENT SYNDROME; HADDS","url":"https://www.omim.org/entry/617330"},{"mim_id":"609935","title":"EARLY B-CELL FACTOR 4; EBF4","url":"https://www.omim.org/entry/609935"},{"mim_id":"609625","title":"CHROMOSOME 10q26 DELETION SYNDROME","url":"https://www.omim.org/entry/609625"},{"mim_id":"607407","title":"EARLY B-CELL FACTOR 3; EBF3","url":"https://www.omim.org/entry/607407"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":15.8}],"url":"https://www.proteinatlas.org/search/EBF3"},"hgnc":{"alias_symbol":["COE3","DKFZp667B0210"],"prev_symbol":[]},"alphafold":{"accession":"Q9H4W6","domains":[{"cath_id":"2.60.40.3180","chopping":"36-234","consensus_level":"high","plddt":95.1976,"start":36,"end":234},{"cath_id":"2.60.40.10","chopping":"263-345","consensus_level":"high","plddt":94.8504,"start":263,"end":345},{"cath_id":"1.10.287.4280","chopping":"350-385","consensus_level":"medium","plddt":85.6881,"start":350,"end":385}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4W6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4W6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4W6-F1-predicted_aligned_error_v6.png","plddt_mean":70.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EBF3","jax_strain_url":"https://www.jax.org/strain/search?query=EBF3"},"sequence":{"accession":"Q9H4W6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H4W6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H4W6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4W6"}},"corpus_meta":[{"pmid":"29563184","id":"PMC_29563184","title":"Stem cell niche-specific Ebf3 maintains the bone marrow cavity.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29563184","citation_count":138,"is_preprint":false},{"pmid":"28017372","id":"PMC_28017372","title":"A Syndromic Neurodevelopmental Disorder Caused by De Novo Variants in EBF3.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28017372","citation_count":92,"is_preprint":false},{"pmid":"29298096","id":"PMC_29298096","title":"Long Noncoding RNA EBF3-AS Promotes Neuron Apoptosis in Alzheimer's Disease.","date":"2018","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29298096","citation_count":84,"is_preprint":false},{"pmid":"28017373","id":"PMC_28017373","title":"Mutations in EBF3 Disturb Transcriptional Profiles and Cause Intellectual Disability, Ataxia, and Facial Dysmorphism.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28017373","citation_count":63,"is_preprint":false},{"pmid":"28017370","id":"PMC_28017370","title":"De Novo Mutations in EBF3 Cause a Neurodevelopmental Syndrome.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28017370","citation_count":58,"is_preprint":false},{"pmid":"17018599","id":"PMC_17018599","title":"An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018599","citation_count":55,"is_preprint":false},{"pmid":"28030832","id":"PMC_28030832","title":"Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28030832","citation_count":54,"is_preprint":false},{"pmid":"31383000","id":"PMC_31383000","title":"Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31383000","citation_count":39,"is_preprint":false},{"pmid":"20029986","id":"PMC_20029986","title":"HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20029986","citation_count":37,"is_preprint":false},{"pmid":"21387304","id":"PMC_21387304","title":"Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinoma.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21387304","citation_count":34,"is_preprint":false},{"pmid":"25609158","id":"PMC_25609158","title":"Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.","date":"2015","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/25609158","citation_count":28,"is_preprint":false},{"pmid":"34256850","id":"PMC_34256850","title":"Coding and noncoding variants in EBF3 are involved in HADDS and simplex autism.","date":"2021","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34256850","citation_count":27,"is_preprint":false},{"pmid":"29162653","id":"PMC_29162653","title":"De novo variants in EBF3 are associated with hypotonia, developmental delay, intellectual disability, and autism.","date":"2017","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/29162653","citation_count":27,"is_preprint":false},{"pmid":"25192643","id":"PMC_25192643","title":"Ebf3-miR218 regulation is involved in the development of dopaminergic neurons.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25192643","citation_count":26,"is_preprint":false},{"pmid":"23456299","id":"PMC_23456299","title":"Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis.","date":"2013","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/23456299","citation_count":24,"is_preprint":false},{"pmid":"37271497","id":"PMC_37271497","title":"Circadian clock protein Bmal1 accelerates acute myeloid leukemia by inhibiting ferroptosis through the EBF3/ALOX15 axis.","date":"2023","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/37271497","citation_count":22,"is_preprint":false},{"pmid":"28487885","id":"PMC_28487885","title":"Novel de novo variant in EBF3 is likely to impact DNA binding in a patient with a neurodevelopmental disorder and expanded phenotypes: patient report, in silico functional assessment, and review of published cases.","date":"2017","source":"Cold Spring Harbor molecular case studies","url":"https://pubmed.ncbi.nlm.nih.gov/28487885","citation_count":22,"is_preprint":false},{"pmid":"29750239","id":"PMC_29750239","title":"MiR-23b-3p induces the proliferation and metastasis of esophageal squamous cell carcinomas cells through the inhibition of EBF3.","date":"2018","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/29750239","citation_count":21,"is_preprint":false},{"pmid":"37880234","id":"PMC_37880234","title":"Ebf3+ niche-derived CXCL12 is required for the localization and maintenance of hematopoietic stem cells.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37880234","citation_count":21,"is_preprint":false},{"pmid":"29258872","id":"PMC_29258872","title":"Prdm13 is required for Ebf3+ amacrine cell formation in the retina.","date":"2017","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29258872","citation_count":19,"is_preprint":false},{"pmid":"34906623","id":"PMC_34906623","title":"EBF3 reactivation by inhibiting the EGR1/EZH2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinoma.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34906623","citation_count":19,"is_preprint":false},{"pmid":"29062322","id":"PMC_29062322","title":"Whole Gene Deletion of EBF3 Supporting Haploinsufficiency of This Gene as a Mechanism of Neurodevelopmental Disease.","date":"2017","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29062322","citation_count":18,"is_preprint":false},{"pmid":"29869132","id":"PMC_29869132","title":"The caudo-ventral pallium is a novel pallial domain expressing Gdf10 and generating Ebf3-positive neurons of the medial amygdala.","date":"2018","source":"Brain structure & function","url":"https://pubmed.ncbi.nlm.nih.gov/29869132","citation_count":16,"is_preprint":false},{"pmid":"30587576","id":"PMC_30587576","title":"Coupled monoubiquitylation of the co-E3 ligase DCNL1 by Ariadne-RBR E3 ubiquitin ligases promotes cullin-RING ligase complex remodeling.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30587576","citation_count":14,"is_preprint":false},{"pmid":"34999443","id":"PMC_34999443","title":"Duplication/triplication mosaicism of EBF3 and expansion of the EBF3 neurodevelopmental disorder phenotype.","date":"2021","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/34999443","citation_count":13,"is_preprint":false},{"pmid":"35340043","id":"PMC_35340043","title":"An Integrated Phenotypic and Genotypic Approach Reveals a High-Risk Subtype Association for EBF3 Missense Variants Affecting the Zinc Finger Domain.","date":"2022","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35340043","citation_count":13,"is_preprint":false},{"pmid":"34050706","id":"PMC_34050706","title":"Clinical spectrum of individuals with de novo EBF3 variants or deletions.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34050706","citation_count":12,"is_preprint":false},{"pmid":"29113800","id":"PMC_29113800","title":"A Prdm8 target gene Ebf3 regulates multipolar-to-bipolar transition in migrating neocortical cells.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29113800","citation_count":11,"is_preprint":false},{"pmid":"29913442","id":"PMC_29913442","title":"Associations of Pulmonary Fibrosis with Peripheral Blood Th1/Th2 Cell Imbalance and EBF3 Gene Methylation in Uygur Pigeon Breeder's Lung Patients.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29913442","citation_count":10,"is_preprint":false},{"pmid":"32398354","id":"PMC_32398354","title":"Transient and lineage-restricted requirement of Ebf3 for sternum ossification.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32398354","citation_count":6,"is_preprint":false},{"pmid":"34177436","id":"PMC_34177436","title":"Neuroimaging Findings in Patients with EBF3 Mutations: Report of Two Cases.","date":"2021","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/34177436","citation_count":6,"is_preprint":false},{"pmid":"37090941","id":"PMC_37090941","title":"Neurologic, Neuropsychologic, and Neuroradiologic Features of EBF3-Related Syndrome.","date":"2023","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37090941","citation_count":5,"is_preprint":false},{"pmid":"36937983","id":"PMC_36937983","title":"Further delineation of EBF3-related syndromic neurodevelopmental disorder in twelve Chinese patients.","date":"2023","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36937983","citation_count":5,"is_preprint":false},{"pmid":"38479556","id":"PMC_38479556","title":"Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38479556","citation_count":5,"is_preprint":false},{"pmid":"39821672","id":"PMC_39821672","title":"Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.","date":"2025","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/39821672","citation_count":4,"is_preprint":false},{"pmid":"34367240","id":"PMC_34367240","title":"A Novel de novo Mutation in EBF3 Associated With Hypotonia, Ataxia, and Delayed Development Syndrome in a Chinese Boy.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34367240","citation_count":4,"is_preprint":false},{"pmid":"40264043","id":"PMC_40264043","title":"SNORA47 affects stemness and chemotherapy sensitivity via EBF3/RPL11/c-Myc axis in luminal A breast cancer.","date":"2025","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/40264043","citation_count":3,"is_preprint":false},{"pmid":"38473261","id":"PMC_38473261","title":"Targeted DNA Methylation Editing Using an All-in-One System Establishes Paradoxical Activation of EBF3.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38473261","citation_count":2,"is_preprint":false},{"pmid":"39896160","id":"PMC_39896160","title":"MiR-301b-3p targets and regulates EBF3 to impact the stem-like phenotype of breast cancer cells through glycolysis.","date":"2024","source":"Journal of clinical biochemistry and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/39896160","citation_count":2,"is_preprint":false},{"pmid":"40073166","id":"PMC_40073166","title":"A nonsense variant in the C-terminal transactivation domain of the EBF3 gene in an individual with intellectual disability and behavioural disorder: case report and literature review.","date":"2025","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40073166","citation_count":1,"is_preprint":false},{"pmid":"41081394","id":"PMC_41081394","title":"Generation and characterization of a knockout mouse of an enhancer of EBF3.","date":"2025","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/41081394","citation_count":0,"is_preprint":false},{"pmid":"39829799","id":"PMC_39829799","title":"Generation and Characterization of a Knockout Mouse of an Enhancer of EBF3.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39829799","citation_count":0,"is_preprint":false},{"pmid":"41270467","id":"PMC_41270467","title":"EBF3 transcriptionally activates ACADL to block the Hippo/YAP signaling pathway and inhibits breast cancer progression.","date":"2025","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/41270467","citation_count":0,"is_preprint":false},{"pmid":"42018103","id":"PMC_42018103","title":"EBF3 suppresses lung adenocarcinoma progression and immune evasion via transcriptional repression of CCL24.","date":"2026","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/42018103","citation_count":0,"is_preprint":false},{"pmid":"39109108","id":"PMC_39109108","title":"Augmentation Cystoplasty in a Girl With Early B-cell Factor 3 (EBF3)-Related Syndrome.","date":"2024","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/39109108","citation_count":0,"is_preprint":false},{"pmid":"18845077","id":"PMC_18845077","title":"[Construction of eukaryotic expression vector for EBF3 and EGFP fusion protein and its expression in HepG2 cells].","date":"2008","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18845077","citation_count":0,"is_preprint":false},{"pmid":"36317217","id":"PMC_36317217","title":"[Analysis of clinical features and EBF3 gene variant in a child with hypotonia, ataxia and developmental delay].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36317217","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.21.671508","title":"Evolution of Cajal-Retzius Cells in Vertebrates from an Ancient Class of Tp73+ Neurons","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.21.671508","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.21.671455","title":"Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration","date":"2025-08-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.21.671455","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.09.631762","title":"Generation and Characterization of a Knockout Mouse of an Enhancer of <i>EBF3</i>","date":"2025-01-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.09.631762","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.10.658830","title":"FOXP1 differentially regulates the development of murine vasopressin and oxytocin magnocellular neurons","date":"2025-06-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.10.658830","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.10.612287","title":"Disrupted development of sensory systems and the cerebellum in a zebrafish<i>ebf3a</i>mutant","date":"2024-09-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.10.612287","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.17.613303","title":"Endothelial regulatory circuits control cranial neural crest migration and plasticity","date":"2024-09-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.17.613303","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":28158,"output_tokens":4272,"usd":0.074277},"stage2":{"model":"claude-opus-4-6","input_tokens":7770,"output_tokens":3343,"usd":0.183638},"total_usd":0.257915,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"EBF3 directly binds the p21(cip1/waf1) promoter and regulates transcription from both p21(cip1/waf1) and p27(kip1) promoters, inducing cell cycle arrest and apoptosis with caspase-3 activation; cyclin-dependent kinase inhibitors p27(kip1) and p57(kip2) are persistently activated while cell survival/proliferation genes are suppressed.\",\n      \"method\": \"Reporter assays, chromatin immunoprecipitation (ChIP), overexpression with functional readouts (cell cycle analysis, caspase-3 activation)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct promoter binding by ChIP + reporter assay + functional phenotype with defined targets\",\n      \"pmids\": [\"17018599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"De novo missense variants in EBF3 affecting a conserved zinc finger motif reduce transcriptional activity and the ability to form heterodimers with wild-type EBF3, establishing that DNA binding and dimerization are required for EBF3 function in brain development.\",\n      \"method\": \"Transactivation (luciferase) assays, heterodimer formation assays with mutant proteins in cell lines, structural modeling\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal functional assays (transcriptional activation, dimerization) across two independent publications\",\n      \"pmids\": [\"28017370\", \"28017372\", \"28017373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"EBF3 missense mutations affecting the DNA-binding domain cause mislocalization of mutant proteins to the cytoplasm and reduce chromatin association, as demonstrated by subcellular fractionation; mutant EBF3 has reduced genome-wide DNA binding and gene-regulatory activity by ChIP-seq and RNA-seq.\",\n      \"method\": \"Subcellular fractionation, in situ chromatin association assay, ChIP-seq, RNA-seq, transactivation assays in HEK293T cells\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (fractionation, ChIP-seq, RNA-seq, reporter assay) in a single rigorous study\",\n      \"pmids\": [\"28017373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ebf3 is a target of miR-218 during dopaminergic (DA) neuron development; overexpression of Ebf3 at the neural precursor stage increases TH+ DA neuron number, while suppression reduces it, and miR-218-mediated regulation of Ebf3 controls terminal differentiation of DA neurons.\",\n      \"method\": \"Overexpression and knockdown in ES cell differentiation system, miRNA target validation, cell counting of TH+ neurons\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — gain/loss-of-function with specific cellular phenotype, miRNA-target relationship shown\",\n      \"pmids\": [\"25192643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Ebf3 is a target gene of the transcription factor Prdm8; Ebf3 knockdown causes severe defects in leading process formation and inhibits the multipolar-to-bipolar transition of migrating neocortical neurons. Ebf3 positively regulates NeuroD1 transcription and NeuroD1 overexpression partially rescues the migration defect.\",\n      \"method\": \"In utero electroporation-based knockdown, morphological analysis of migrating neurons, NeuroD1 overexpression rescue\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular phenotype (migration defect) and partial genetic rescue\",\n      \"pmids\": [\"29113800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ebf3 is expressed in CXCL12-abundant reticular (CAR)/LepR+ mesenchymal stem cells of bone marrow; deletion of Ebf3 in these cells impairs HSC niche function and causes osteosclerosis. Combined deletion of Ebf1 and Ebf3 leads to osteoblast differentiation of CAR cells with reduced HSC niche factor expression and complete marrow cavity occlusion, demonstrating that Ebf3 maintains mesenchymal stem cell identity and inhibits osteoblast differentiation.\",\n      \"method\": \"Conditional knockout mice, lineage tracing, histology, HSC functional assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with defined cellular and organismal phenotype, lineage tracing, replicated with double KO\",\n      \"pmids\": [\"29563184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EBF3-EGFP fusion protein localizes predominantly to the nucleus when expressed in HepG2 cells, establishing nuclear localization of EBF3.\",\n      \"method\": \"Fluorescence microscopy and Western blot of nuclear/cytoplasmic fractions of transfected cells\",\n      \"journal\": \"Xi bao yu fen zi mian yi xue za zhi\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single localization experiment, no functional consequence tested\",\n      \"pmids\": [\"18845077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EBF3 directly binds the Vimentin promoter to transcriptionally upregulate it, promoting metastasis in nasopharyngeal carcinoma; EBF3 is epigenetically silenced by the EGR1/EZH2/HDAC9 complex via H3K27me3 at its promoter.\",\n      \"method\": \"ChIP, promoter reporter assays, RNA-seq, epigenetic complex characterization\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct promoter binding shown by ChIP, epigenetic regulation mechanism identified with complex components\",\n      \"pmids\": [\"34906623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Bmal1 recruits EZH2 to the EBF3 promoter to enhance H3K27me3-mediated methylation and suppress EBF3 expression; EBF3 in turn binds the ALOX15 promoter to enhance its expression and promote ferroptosis, establishing the Bmal1/EZH2 → EBF3 → ALOX15 → ferroptosis axis in AML.\",\n      \"method\": \"ChIP, promoter reporter assays, knockdown/overexpression, in vivo xenograft model, ferroptosis biochemical assays\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-validated direct promoter binding at both steps of the pathway, in vivo confirmation\",\n      \"pmids\": [\"37271497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL12 deletion from Ebf3+/LepR+ CAR cells markedly reduces HSCs and impairs their ability to generate B cell progenitors; CXCL12 maintains lymphoid-biased HSC repopulating ability in vitro, demonstrating that CAR cell-derived CXCL12 is required for HSC localization and lymphoid-biased maintenance.\",\n      \"method\": \"Conditional CXCL12 deletion from Ebf3+ cells, transplantation assays, in vitro CXCL12 treatment of HSCs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with specific cellular phenotype, transplantation rescue, in vitro validation\",\n      \"pmids\": [\"37880234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ebf3 is required in lateral plate mesenchyme cells (particularly tendon/connective tissue cells) at embryonic day 9.5–10.5 for sternum ossification; Ebf3 knockout leads to defective Runx2+ pre-osteoblast generation without affecting chondrogenesis, with upregulation of Egr1/2, Osr1 and Islet1+ cells and downregulation of Shox2.\",\n      \"method\": \"Knockout and conditional/temporal knockout mice, cell lineage analysis, gene expression profiling\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional and temporal KO with defined cellular phenotype and downstream gene expression changes\",\n      \"pmids\": [\"32398354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EBF3 binds the CNTNAP4 promoter and directly activates CNTNAP4 transcription, protecting dopaminergic neurons from apoptosis in a Parkinson's disease model; m6A methylation (regulated by FTO) controls EBF3 mRNA stability and expression.\",\n      \"method\": \"Luciferase reporter assay, ChIP, DNA pulldown assay, CNTNAP4 knockdown rescue experiment, in vivo MPTP mouse model\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct promoter binding confirmed by ChIP and DNA pulldown, functional rescue by target knockdown\",\n      \"pmids\": [\"38479556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"EBF3 transcriptionally activates ACADL by binding to its promoter, blocking nuclear YAP localization and canonical Hippo/YAP target genes (CTGF, CYR61, ANKRD1) to suppress breast cancer cell growth.\",\n      \"method\": \"Promoter binding assays, luciferase reporter, ACADL knockdown rescue, xenograft tumor model\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding shown, pathway placement via rescue experiment and in vivo model\",\n      \"pmids\": [\"41270467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"EBF3 transcriptionally represses CCL24 to remodel the tumor immune microenvironment in lung adenocarcinoma, reducing M2-like macrophage infiltration and increasing CD4+/CD8+ T cell recruitment; EBF3 also suppresses AKT and P38 phosphorylation.\",\n      \"method\": \"Overexpression/knockdown, ChIP/reporter assays for CCL24, conditioned medium macrophage polarization assay, syngeneic mouse model with immune flow cytometry, CCL24 rescue experiment\",\n      \"journal\": \"Cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional repression of CCL24 validated, in vivo rescue with exogenous CCL24 confirms mechanism\",\n      \"pmids\": [\"42018103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SNORA47 interacts with EBF3 to facilitate translocation of ribosomal protein L11 (RPL11), which modulates c-Myc levels, establishing a SNORA47-EBF3-RPL11-c-Myc axis controlling breast cancer stemness.\",\n      \"method\": \"Co-immunoprecipitation/interaction assays, overexpression/knockdown with phenotypic readouts\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, interaction assay without rigorous mechanistic follow-up of EBF3's direct role\",\n      \"pmids\": [\"40264043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EBF3 missense variants disrupting the zinc finger domain (ZNF) fail to restore viability in Drosophila and impair transcriptional activation in luciferase assays, whereas the recurrent DBD variant p.Arg209Trp partially rescues fly viability and preserves transcriptional activation, establishing a genotype-severity correlation.\",\n      \"method\": \"In vivo Drosophila UAS-GAL4 rescue assays, in vitro luciferase transcriptional activation assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — two orthogonal functional assays (in vivo fly model + in vitro reporter) applied to multiple variants\",\n      \"pmids\": [\"35340043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Missense variants in the zinc knuckle of EBF3's DNA binding domain reduce DNA affinity, as predicted by homology-based atomic modeling and molecular dynamics simulations, consistent with experimental data for the paralogous residue in EBF1.\",\n      \"method\": \"Homology-based structural modeling, molecular dynamics simulations\",\n      \"journal\": \"Cold Spring Harbor molecular case studies\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational/in silico prediction, no direct experimental validation of EBF3 structure\",\n      \"pmids\": [\"28487885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EBF3 binds promoters of neurodevelopmental disorder (NDD) genes in neuronal cells as shown by ChIP-seq, with enrichment for binding NDD genes involved in gene regulation (p=7.43×10-6, OR=1.87).\",\n      \"method\": \"ChIP-seq in neuronal cells, gene enrichment analysis\",\n      \"journal\": \"Human genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq with statistical enrichment analysis in relevant cell type\",\n      \"pmids\": [\"34256850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In zebrafish ebf3a loss-of-function mutants, the cerebellum, hypothalamus, and hindbrain are smaller, cerebellar activity is strongly increased, and genes marking olfactory sensory neurons, the lateral line, and cerebellar Purkinje neurons are significantly downregulated, establishing Ebf3's role in sensory system and cerebellar development.\",\n      \"method\": \"Loss-of-function zebrafish mutant, RNA-sequencing, brain activity imaging, behavioral assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and transcriptomic phenotype in an ortholog model\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"EBF3 is a nuclear transcription factor with an atypical zinc finger/helix-loop-helix DNA-binding domain that directly binds promoters of target genes (including p21, p27, CDKN1A, Vimentin, ALOX15, CNTNAP4, ACADL, CCL24) to activate or repress transcription; disease-causing mutations in its zinc finger or DNA-binding domain cause nuclear mislocalization, reduced chromatin association, and loss of transcriptional activation, leading to a neurodevelopmental syndrome (HADDS); in the bone marrow niche it maintains mesenchymal stem cell identity and prevents osteoblast differentiation; in neurons it regulates dopaminergic differentiation, neocortical neuronal migration via NeuroD1, and cerebellar/sensory development; and its expression is itself controlled by epigenetic mechanisms including EZH2/H3K27me3, m6A mRNA modification, and miRNA targeting.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"EBF3 is a sequence-specific transcription factor that controls cell fate decisions in neuronal, mesenchymal, and hematopoietic lineages by directly binding target gene promoters to activate or repress transcription. It recognizes DNA through an atypical zinc finger/helix-loop-helix domain and functions as a homodimer or heterodimer; disease-causing mutations in the zinc finger or DNA-binding domain cause cytoplasmic mislocalization, reduced chromatin association, and impaired transcriptional activation, resulting in the neurodevelopmental disorder HADDS (hypotonia, ataxia, and delayed development syndrome) [PMID:28017370, PMID:28017373, PMID:35340043]. In bone marrow, EBF3 maintains CXCL12-abundant reticular mesenchymal stem cell identity and suppresses osteoblast differentiation, while in neurons it promotes dopaminergic differentiation, regulates neocortical migration through NeuroD1 activation, and controls cerebellar and sensory neuron development [PMID:29563184, PMID:25192643, PMID:29113800]. EBF3 directly activates diverse target promoters including CDKN1A/p21, Vimentin, ALOX15, CNTNAP4, and ACADL, and represses CCL24; its own expression is regulated epigenetically by EZH2-mediated H3K27 trimethylation and post-transcriptionally by m6A modification and miR-218 [PMID:17018599, PMID:34906623, PMID:37271497, PMID:38479556, PMID:42018103].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that EBF3 is a direct transcriptional activator of cell cycle inhibitor genes answered the fundamental question of how EBF3 exerts growth-suppressive effects — by binding the p21 promoter and inducing p21/p27-dependent cell cycle arrest and apoptosis.\",\n      \"evidence\": \"ChIP showing direct p21 promoter binding, reporter assays, and cell cycle/caspase-3 analysis upon EBF3 overexpression\",\n      \"pmids\": [\"17018599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous contexts where EBF3 regulates p21/p27 not defined\", \"Whether EBF3-mediated apoptosis requires p21/p27 or operates through parallel targets not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that miR-218 targets Ebf3 during dopaminergic neuron differentiation established a post-transcriptional control layer and revealed EBF3 as a dose-sensitive regulator of terminal DA neuron fate.\",\n      \"evidence\": \"Gain- and loss-of-function in ES cell–derived DA neuron differentiation, miR-218 target validation, TH+ neuron quantification\",\n      \"pmids\": [\"25192643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Ebf3 transcriptional targets in DA neurons not identified\", \"In vivo relevance of miR-218/Ebf3 axis in DA neuron development not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of de novo EBF3 mutations in patients with neurodevelopmental disease, combined with demonstration that zinc finger and DNA-binding domain mutations abolish transcriptional activation, dimerization, nuclear retention, and genome-wide chromatin occupancy, established the molecular basis of HADDS and defined EBF3 as a haploinsufficient transcription factor requiring DNA binding and dimerization for function.\",\n      \"evidence\": \"Patient genetics, luciferase transactivation, dimerization assays, subcellular fractionation, ChIP-seq, and RNA-seq in HEK293T cells\",\n      \"pmids\": [\"28017370\", \"28017372\", \"28017373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of the EBF3 DNA-binding domain to explain variant-specific effects\", \"Neuronal cell-type–specific consequences of mutations not characterized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that Ebf3 knockdown disrupts the multipolar-to-bipolar transition in migrating neocortical neurons and that NeuroD1 overexpression partially rescues this defect identified a specific downstream pathway through which EBF3 controls cortical neuron migration.\",\n      \"evidence\": \"In utero electroporation knockdown in mouse neocortex, morphological analysis, NeuroD1 rescue\",\n      \"pmids\": [\"29113800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EBF3 directly binds NeuroD1 promoter not shown\", \"Cell-autonomous vs. non-autonomous effects not distinguished\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Conditional deletion of Ebf3 (alone and with Ebf1) in CAR/LepR+ bone marrow mesenchymal cells revealed that EBF3 maintains mesenchymal stem cell identity and prevents osteoblast differentiation, directly linking EBF3 to hematopoietic niche function.\",\n      \"evidence\": \"Conditional knockout mice with lineage tracing, histology showing osteosclerosis, HSC functional assays\",\n      \"pmids\": [\"29563184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating the anti-osteoblast program not identified\", \"Relative contribution of EBF3 vs. EBF1 in single cells not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ChIP-seq in neuronal cells revealed genome-wide enrichment of EBF3 binding at promoters of neurodevelopmental disorder genes, providing a mechanistic link between EBF3 transcriptional targets and the neurodevelopmental phenotype of HADDS patients.\",\n      \"evidence\": \"ChIP-seq in neuronal cells with statistical enrichment for NDD gene promoters\",\n      \"pmids\": [\"34256850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional validation of individual NDD gene targets not performed\", \"Whether EBF3 activates or represses these NDD targets not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that the EGR1/EZH2/HDAC9 complex silences EBF3 via H3K27me3 at its promoter, and that EBF3 directly activates Vimentin transcription, established an epigenetic switch controlling EBF3 expression and identified a pro-metastatic transcriptional target.\",\n      \"evidence\": \"ChIP and reporter assays at the EBF3 and Vimentin promoters, epigenetic complex characterization in nasopharyngeal carcinoma\",\n      \"pmids\": [\"34906623\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EZH2-mediated EBF3 silencing operates in normal developmental contexts not tested\", \"Vimentin as sole mediator of metastatic phenotype not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Functional testing of multiple EBF3 patient variants using Drosophila rescue and luciferase assays established a genotype-severity correlation, showing zinc finger mutations are more damaging than certain DNA-binding domain mutations.\",\n      \"evidence\": \"UAS-GAL4 rescue of Drosophila lethality with variant EBF3 constructs and luciferase transcriptional assays\",\n      \"pmids\": [\"35340043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Drosophila model does not recapitulate human brain-specific phenotypes\", \"Structural basis for differential severity of ZNF vs. DBD variants remains computational\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The Bmal1/EZH2→EBF3→ALOX15 axis in AML cells extended the epigenetic regulation paradigm and identified EBF3 as a transcriptional activator of ALOX15 that promotes ferroptosis, providing a functional context beyond development.\",\n      \"evidence\": \"ChIP at EBF3 and ALOX15 promoters, knockdown/overexpression, ferroptosis assays, xenograft model in AML\",\n      \"pmids\": [\"37271497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EBF3-driven ferroptosis operates in non-malignant hematopoietic cells unknown\", \"Specificity of Bmal1 recruitment of EZH2 to EBF3 vs. other loci not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Conditional CXCL12 deletion from Ebf3+ cells demonstrated that the EBF3-marked CAR niche specifically maintains HSC localization and lymphoid-biased repopulating ability via CXCL12, refining the niche model.\",\n      \"evidence\": \"Conditional CXCL12 KO from Ebf3-Cre+ cells, transplantation assays, in vitro CXCL12 treatment\",\n      \"pmids\": [\"37880234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EBF3 directly regulates CXCL12 transcription not tested\", \"Heterogeneity within Ebf3+ CAR cells not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that FTO-regulated m6A modification controls EBF3 mRNA stability, and that EBF3 directly activates CNTNAP4 to protect DA neurons from apoptosis, added a post-transcriptional regulatory layer and a neuroprotective target gene.\",\n      \"evidence\": \"ChIP and DNA pulldown at the CNTNAP4 promoter, CNTNAP4 knockdown rescue, MPTP Parkinson's disease mouse model\",\n      \"pmids\": [\"38479556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A sites on EBF3 mRNA not mapped\", \"Whether CNTNAP4 activation is relevant to HADDS neuropathology unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of EBF3 as a transcriptional activator of ACADL (blocking YAP nuclear localization) and a repressor of CCL24 (remodeling tumor immune microenvironment) expanded the target repertoire to include Hippo pathway modulation and immune regulation.\",\n      \"evidence\": \"Promoter binding/reporter assays, rescue experiments, xenograft and syngeneic mouse models in breast and lung cancer\",\n      \"pmids\": [\"41270467\", \"42018103\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ACADL-mediated YAP suppression is relevant to non-cancer contexts not addressed\", \"Direct mechanism by which EBF3 represses (vs. activates) transcription at CCL24 not elucidated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of EBF3 DNA recognition and dimerization, the complete neuronal target gene program explaining HADDS pathogenesis, the mechanism by which EBF3 switches between transcriptional activation and repression, and whether EBF3's roles in mesenchymal stem cell maintenance and neuronal development share common transcriptional targets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimentally determined structure of EBF3\", \"Genome-wide target analysis in disease-relevant neuronal subtypes lacking\", \"Activation vs. repression mechanism at different promoters unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 7, 8, 11, 12, 13, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 7, 8, 11, 12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [2, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 2, 7, 8, 11, 12, 13, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 4, 5, 10, 18]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EBF1\",\n      \"EZH2\",\n      \"NEUROD1\",\n      \"PRDM8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}